Smoking Cessation and Nicotine De-addiction Products Market

Sravanthi Rudroju

49
views

Smoking Cessation and Nicotine De-addiction Products Market size is estimated to reach $37.2 billion by 2027, and is poised to grow at a CAGR of 9.7% over the forecast period of 2022-2027.

Smoking Cessation and Nicotine De-addiction Products Market size is estimated to reach $37.2 billion by 2027, and is poised to grow at a CAGR of 9.7% over the forecast period of 2022-2027. Smoking cessation or nicotine de-addiction involves tobacco discontinuation which lowers the risk of cancer and other serious health problems. Smoking includes usage of tobacco which contain nicotine that creates addiction in consumers by releasing the neurotransmitters such as glutamate, zyban, dopamine and gamma-aminobutyric acid (GABA). People who want to quit smoking can take advantage of nicotine replacement therapy (NRT), electronic cigarettes and therapeutic medication such as anti-depressants and nicotine receptor agonists such as cytisine and varenicline to treat tobacco dependency. To reduce nicotine addiction, the government of varioius economies emphasizes strict regulation and prohibited smoking in public areas to control nicotine and cigarette addiction owing to its toxic effects on cardiac and respiratory systems. In many countries, the government strictly warns tobacco product companies to print a hazardous warning on the label of products to discourage people from consuming. Also, increasing government and organizational initiatives to remove people from tobacco addiction helps to drive the Smoking Cessation and Nicotine De-addiction Products industry over the forecast period 2022-2027.

Smoking Cessation and Nicotine De-addiction Products Market Report Coverage

The report: “Smoking Cessation and Nicotine De-addiction Products Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Smoking Cessation and Nicotine De-addiction Products Market.

By Product Type: Nicotine Replacement Therapy Products (Nicotine Lozenges, Nicotine Gums, Nicotine Sprays, Nicotine Transdermal Patches) Drug Therapy (Zyban (Bupropion), Chantix (varenicline), Cytisine, Nicotine Sublingual Tablets, Nicotine Inhalers, E-Cigarettes (Modular, Disposable, Rechargeable)
By Distribution Channels: Drug Store, Hospital Pharmacies, Online Pharmacies and Retail Pharmacies.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of the World (the Middle East and Africa).

Key Takeaways

Geographically, North America held a dominant market share in the year 2021, owing to the increasing number of smoking adults.
Increasing awareness about the health-hazardous effects of tobacco drives Smoking Cessation and Nicotine De-addiction Products Market over the forecast period 2022-2027.
Strict Regulatory authority and increasing failure of e-cigarettes in the market will negatively impact the Smoking Cessation and Nicotine De-addiction Products industry in the projected forecast period.
A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Smoking Cessation and Nicotine De-addiction Products Market Report.

Smoking Cessation and Nicotine De-addiction Products Market: Market Share (%) by region, 2021

Smoking Cessation and Nicotine De-addiction Products Market

For more details on this report - Request for Sample

Smoking Cessation and Nicotine De-addiction Products Market Segmentation Analysis- By Product Type

Smoking Cessation and Nicotine De-addiction Products Market based on product type can be further segmented into Nicotine Replacement Therapy (NRT) Products (Nicotine Lozenges, Nicotine Gums, Nicotine Sprays, Nicotine Transdermal Patches) Drug Therapy (Zyban (Bupropion), Chantix (varenicline), Cytisine, Nicotine Sublingual Tablets, Nicotine Inhalers, E-Cigarettes (Modular, Disposable, Rechargeable). Nicotine Replacement Therapy Products segment held a dominant Smoking Cessation and Nicotine De-addiction Products Market share in the year 2021. Nicotine is the main addictive substance in tobacco which results in the release of glutamate. Nicotine replacement therapy gives consumers nicotine in form of Nicotine Lozenges, Nicotine Gums, Nicotine Sprays, Nicotine Transdermal Patches and without any harmful chemicals that are present in tobacco. NRT helps to relieve physical symptoms which occurred during quitting tobacco, reduces glutamate release and helps to focus on psychological (emotional) aspects of quitting. Also, NRT is the first method approved by the FDA and many products like Nicotex, Nicogum, Smokefree and KwikNic of the (NRT) brands available in the smoking cessation and nicotine de-addiction products industry that drive the market.

However, E-Cigarette is estimated to be the fastest-growing with a CAGR of 10.9% over the forecast period of 2022-2027. This is majorly owing to the increasing preference of smokers who wants to quit smoking. It is also famous for names such as “e-cigs,” “vapes,” “e-hookahs,” “vape pens,” and “electronic nicotine delivery systems (ENDS).” In 2020, 3.7 % of U.S adults smoke E-cigarettes as per CDC and 22.44 million units in June 2021. Also, FDA approved the flavor enforcement policy in February 2020, which result in a hike in sales by 51% from February 2020 to June 2021. Such an increasing trend of smoking E-Cigarettes helps to grow the segment of the Smoking Cessation and Nicotine De-addiction Products Market over the forecast period.

Smoking Cessation and Nicotine De-addiction Products Market Segmentation Analysis- By Distribution Channels

The Smoking Cessation and Nicotine De-addiction Products Market based on distribution channels can be further segmented into Drug stores, Hospital Pharmacies, Online Pharmacies and Retail Pharmacies. Online Pharmacy held a dominant Smoking Cessation and Nicotine De-addiction Products Market share in 2021 and is estimated to be the fastest-growing with a CAGR of 10.2% over the forecast period of 2022-2027. This is owing to an increased number of smartphone users around the world and the presence of Smoking Cessation and Nicotine De-addiction Products on commercial websites, where anyone can purchase them. According to Data-re-portal 5 billion people around the world use the internet in 2022. And as per OBERLO 2.14millions are digital buyers. As per the tobacco-free-kids organization report published in 2021, Studies have found that youth successfully purchased e-cigarettes over the internet in 94% to 97% of their online purchase attempts. Such increasing use of technology and accessibility to mobile and internet to children and youth increase the online purchase of Smoking Cessation and Nicotine De-addiction Products for use under peer pressure. A study report by Jamaica Hospital Medical Center reported rate of smoking among teens that have three or more friends who smoke is 10 times higher than those that reported none of their friends smoke. Such an increasing number of smokers in broad categories from teens, adults, to elderly people and easy purchase of this product on e-commerce website helps to grow segment over the forecast period.

Smoking Cessation and Nicotine De-addiction Products Market Segmentation Analysis by Geography

The Smoking Cessation and Nicotine De-addiction Products Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant market Smoking Cessation and Nicotine De-addiction Products Market share of 36% in the year 2021 owing to the increasing habit of smoking among adults in America and an increasing number of deaths attributed to smoking. In the United States, over 480,000 deaths from cigarette smoking and over 41,000 deaths from passive smoking are reported each year. Many people in the region have been forced to quit smoking as their understanding of the detrimental effects of smoking has grown. As per CDC, in 2021, 65.3% of youth (middle and high school students) who currently used tobacco products reported that they were seriously thinking about quitting the use of all tobacco products. Such increasing awareness among smokers in North America drives the market for Smoking Cessation and Nicotine De-addiction Products.

Furthermore, Asia-Pacific is estimated to be the fastest-growing with a CAGR of 10.7% over the forecast period 2022-2027, attributed to the high population addicted to tobacco. As per the OECD, library tobacco kills 8 million people every year, 7 million deaths from direct tobacco consumption and 1.2 million deaths of non-smokers exposed to secondhand smoke and 1.6 million deaths occurred in South East Asia Region (SEAR). As per the WHO, the SEAR region accounts for 81% of smokeless tobacco users and is home to 22% of global adult smokers with age 15 years and above. Such a huge number of consumers helps to grow the Smoking Cessation and Nicotine De-addiction Products Market size over the forecast period.

Smoking Cessation and Nicotine De-addiction Products Market Drivers

Increasing Demand for E-cigarettes and Smoking Cessation Products Drives Market Growth.

As a result of the bad impact of tobacco products on human health, many tobacco consumers want to quit their smoking or tobacco chewing habit. As per the United States Department of Health and Human Services, nearly 70% of adults who smoke want to quit smoking in the year 2021. There are 3.4million U.S adults who smoke cigarettes and 3 out of 5 want to quit smoking. As per CDC, in 2021 60.2% of youth reported they had stopped using all tobacco products for one day or longer to quit smoking. Such an increasing number of people who want to stop tobacco addiction helps to grow the Smoking Cessation and Nicotine De-addiction Products Market size.

Increased Deceased Rate due to Smoking drives the industry demand.

Worldwide more than 8 million people are killed by tobacco and which is preventable death as per WHO report 2021. Cancer, heart disease, stroke, lung disease, diabetes and chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, are all linked to smoking. In 2021, about 130180 deaths occurred because of lung cancer, from that 68,820 in men and 61,360 in women as per American Cancer Association. Every year about 1.9 million people die from tobacco-induced heart disease. Such an increasing number of diseases and deaths related to any form of tobacco consumption and smoking resulted in favoring of Smoking Cessation and Nicotine De-addiction Products Market growth.

Smoking Cessation and Nicotine De-addiction Products Market Challenges

Increasing Number of Technical Failure in Products May Limit Market Growth.

FDA announced to recall of more than 5 million e-cigarette products out of the market in 2021. A study from CDC in 2020, reported more than 80 percent of high school students and 70 percent of middle school students use flavored vape products, which can be addictive to such products. In August 2021, FDA ordered three e-cigarette makers to pull out their products from the market, it bans 55,000 flavored e-cigarette products from three vape companies. Such strict regulations and rules may limit the market growth.

Smoking Cessation and Nicotine De-addiction Products Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Smoking Cessation and Nicotine De-addiction Products Market. The top 10- Smoking Cessation and Nicotine De-addiction Products Market companies are-

22nd Century Group, Inc.
Axsome Therapeutics, Inc.
British American Tobacco PLC
Cipla Ltd.
Dr. Reddy’s Laboratories Ltd.
GlaxoSmithKline PLC
Imperial Tobacco Company of India Limited
Itaconix, Japan Tobacco Inc.
Johnson & Johnson
JUUL Labs Inc.

Recent Developments

In May 2022, Axsome Therapeutics receives FDA completes response letter for the new drug application of AXS-07 which is used in the acute treatment of migraine. The new drug application trial was supported by results from two Phase 3 randomized, double-blind, controlled trials of AXS-07 in the acute treatment of migraine, the MOMENTUM and INTERCEPT trials, which demonstrated statistically significant elimination of migraine pain with AXS-07 compared to placebo and active controls.
In January 2022, British American Tobacco PLC, launched virtual research and development visitor experience to showcase world-class science behind next-generation reduced-risk nicotine products. This technology will allow visitors to virtually walk-through BAT R&D labs, meet leading scientists and view the results of new studies in BAT.
In July 2021, 22nd Century Group, Inc.- a leading plant-based biotechnology company focused on tobacco harm reduction and reduced nicotine in tobacco announced a plan to increase investment by securing substantial agreement to expand the distribution network and manufacturing capabilities for the launch of VLN (reduced nicotine content).